Zurich-Schlieren, Switzerland, 12 August 2025

Topadur Pharma AG, a Swiss biopharmaceutical company developing innovative therapies for aging-related diseases, announces the appointment of Professor Thierry Carrel, MD, to its Board of Directors. Professor Carrel is one of Switzerland’s most accomplished cardiac surgeons. His expertise in clinical needs, regulatory navigation, and innovative technologies will provide strategic direction as Topadur moves into its next growth phase. His appointment reinforces Topadur’s commitment to delivering novel therapies through science-driven innovation.

"We are honored to welcome Professor Carrel to our Board," said Dr. Reto Naef, Chairman of the Board and interim CEO of Topadur. "With his exceptional background in academic medicine, cardiovascular surgery, and his experience with global medical innovations, Professor Carrel brings valuable expertise to our team. His contributions come at a time when Topadur is advancing multiple drug candidates through pre-clinical and clinical stages toward first-in-human efficacy data."

Professor Carrel studied medicine at the Universities of Fribourg and Bern, obtaining his MD in 1985 and completing his habilitation at the University of Zurich in 1993. He served as Full Professor and Chairman of the renowned Department of Cardiovascular Surgery at the University of Bern from 1999 until 2020. Throughout his distinguished career, Professor Carrel has performed, taught, or supervised more than 12,000 surgical procedures. He has supported many professorial careers and has authored or co-authored over 850 scientific papers.

His contributions to global cardiovascular innovation extend beyond academia. He has co-founded successful medtech start-ups, including Swiss Cardio Technologies AG and CoreMedic GmbH, and has played an advisory role with numerous cutting-edge companies such as Novostia SA, Xeltis, and Abbott Cardiovascular. Professor Carrel also has a long-standing commitment to humanitarian work, leading pediatric cardiac missions in Russia, Morocco, Uzbekistan, and Mongolia.  

"I'm very honoured to join Topadur, a very innovative biotech company that develops highly promising molecules for the treatment of several diseases affecting an increasing number of patients. The mechanism of tissue healing occurs mainly through a physiological process, which consists in improving blood flow in the smallest vessels. This is exactly what the aging population is waiting for."

About Topadur

Topadur is a patient-oriented Swiss biopharmaceutical company developing disruptive therapies for aging-associated diseases. Topadur has developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase cGMP levels to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Topadur’s R&D portfolio includes promising development candidates in wound healing, medical aesthetics and oncology. For more information regarding Topadur, please visit: www.topadur.com

Contact

Jaan Strang

Communications

+41 44 755 44 66

jaan.strang@topadur.com

DISCLAIMER

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of TOPADUR PHARMA AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

‍

‍